Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

This study is looking for adult patients (18 years or older) who have been diagnosed with a specific type of brain tumour called glioblastoma, which has unfortunately grown back after previous treatment. You would have already received standard treatments like surgery, radiotherapy, and some chemotherapy or other anti-cancer therapies.

Doctors would need to see clear signs that the tumour has grown back, and it needs to be of a certain size shown on a brain scan (MRI). You would also need to be fit enough for surgery, and your body's essential functions, like blood counts and liver, should be working reasonably well. There's also a waiting period after your last cancer treatment before you can join to make sure your body has recovered enough.

Your doctors will carefully check all your medical information and scan results to see if this study is suitable for you. They will explain everything in detail so you can make an informed decision.

Taking part in this study would involve regular hospital visits for assessments, scans (like MRI), and receiving the study treatments. If you are in the group receiving SonoCloud-9 and Carboplatin, the SonoCloud-9 device would be placed at the time of your tumour surgery, and then activated during treatment sessions to open the blood-brain barrier. Both SonoCloud-9 and carboplatin would be given according to a specific schedule over several months. If you are in the control group, you would receive either Lomustine or Temozolomide according to standard treatment schedules.

There will be follow-up appointments to monitor your health and the tumour's response to treatment. The total length of your participation would depend on how your treatment progresses and your doctor's recommendations, but typically involves several months of active treatment and follow-up over a longer period.